Recursion Pharmaceuticals (NASDAQ:RXRX) CEO Najat Khan Sells 23,588 Shares of Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Najat Khan sold 23,588 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the sale, the chief executive officer directly owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. The trade was a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Najat Khan also recently made the following trade(s):

• On Monday, March 9th, Najat Khan sold 28,298 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.35, for a total transaction of $94,798.30.

Recursion Pharmaceuticals Price Performance

RXRX stock opened at $3.32 on Friday. The firm has a 50 day moving average price of $3.30 and a 200-day moving average price of $3.82. Recursion Pharmaceuticals, Inc. has a 52-week low of $2.77 and a 52-week high of $7.18. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -2.77 and a beta of 1.04. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.47 and a current ratio of 5.47.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $15.78 million. During the same period last year, the business earned ($0.50) earnings per share. The business’s revenue was down 56.8% on a year-over-year basis. Equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC purchased a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $31,000. Allworth Financial LP raised its holdings in Recursion Pharmaceuticals by 85.6% in the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock worth $47,000 after acquiring an additional 4,403 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $41,000. IFP Advisors Inc raised its holdings in Recursion Pharmaceuticals by 81.5% in the 3rd quarter. IFP Advisors Inc now owns 10,355 shares of the company’s stock worth $51,000 after acquiring an additional 4,650 shares during the last quarter. Finally, Savant Capital LLC purchased a new position in Recursion Pharmaceuticals in the 3rd quarter worth approximately $54,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on RXRX. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Bank of America lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Morgan Stanley boosted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a report on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.10.

Trending Headlines about Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

• Positive Sentiment: Recursion’s recent business updates highlighted positive early clinical data and further progress in its AI drug-discovery pipeline, reinforcing investor optimism about the company’s long-term platform potential. Why Recursion Pharmaceuticals (RXRX) Is Up 9.5% After AI Pipeline Progress And Stronger-Than-Expected Q1 Results
• Positive Sentiment: The company reported a smaller-than-expected quarterly EPS loss and better-than-expected revenue in its latest earnings release, which helped support the recent rebound in the stock. Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
• Neutral Sentiment: Recent commentary also focused on Recursion’s valuation and the market’s patience with its AI-biotech story, suggesting investors are weighing pipeline upside against a still-uncertain commercialization timeline. Recursion’s AI Drug Pipeline Progress Tests Investor Patience And Valuation
• Negative Sentiment: CEO Najat Khan sold shares in a pre-arranged trading plan, and Director Namandje Bumpus also sold shares, adding a mild overhang as investors may view insider selling cautiously even though the transactions were planned in advance. SEC filing for CEO Najat Khan sale SEC filing for Director Namandje Bumpus sale

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.